FDA clears echo microbubble contrast agent

Evan Godt | | Health Imaging | Echocardiography

The FDA has approved Lumason, the microbubble contrast agent marketed by Bracco Diagnostics.

Lumason enables contrast-enhanced echocardiographic imaging and uses gas-filled microbubbles to reflect sound waves to enhance an image.

 “Sometimes echocardiograms in certain patients are difficult for physicians to see and interpret,” Libero Marzella, MD, PhD, director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research, said in a release. “Today’s approval provides doctors with another option when performing contrast-enhanced ultrasound.”

Lumason will carry a boxed warning about the risk of serious cardiopulmonary reactions, including fatal cardiac or respiratory arrest. These risks may be increased in those with certain heart conditions.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Related Content

ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension
ASE shares new guidelines for ultrasound-guided vascular access
New AI program delivers rapid, accurate echo video assessments
FDA clears AI screening tool for cardiac amyloidosis
FDA approves AI startup’s new software for echo assessments
Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.